BioNTech SE Overview
Valuation check: BNTX's P/E ratio is -12.65, below the Healthcare sector average of 25.72.
Get informed when a big investor buys or sells
+ Follow-12.65
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, BNTX shows a P/E ratio of -12.65. That is below the Healthcare sector average of 25.72. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 25.72. BioNTech SE is at -12.65, which is lower that average. That is roughly 149.2% below the sector mean. Use the comparison chart on this page to see how BNTX stacks up against individual peers as well.
Investors watch BNTX's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. BioNTech SE's latest reading is -12.65. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has BioNTech SE's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -12.65) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 25.72, while BNTX is at -12.65. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
